Siemens Healthineers is pursuing the separation of its Diagnostics business alongside a change in shareholder structure. Its annual results show falling Diagnostics revenue while Imaging grew. The medical technology company also reported higher comparable group revenue and proposed an unchanged dividend, with a new earnings range for the coming fiscal year.
Medical technology company Siemens Healthineers is pursuing a carveout of Diagnostics, its diagnostic testing business, as it considers a different shareholder structure. Chief executive Bernd Montag discussed the separation alongside the fiscal-year results. The company’s stated direction retains the Healthineers brand.[1], [2]
In the fourth fiscal quarter, Diagnostics comparable revenue fell 4.2 per cent, with an adjusted margin of 5.4 per cent. Imaging, the medical imaging business, grew 10 per cent with a margin of 21.9 per cent. Precision Therapy revenue increased 4.8 per cent, with a margin of 13.8 per cent. The group’s quarterly comparable revenue rose 5.9 per cent and the adjusted margin was 15.9 per cent.[1]
For the year ending September 30, comparable revenue grew 4 per cent. Annual revenue was approximately 23.6 billion euros. Adjusted earnings before interest and tax reached approximately 3.8 billion euros, a margin of 16.2 per cent. Adjusted basic earnings per share were 2.42 euros and free cash flow approximately 2.4 billion euros. Management proposed an unchanged dividend of 1 euro per share. For fiscal 2027, it forecasts comparable revenue growth of 4–5 per cent for the company.[1]
